Specific Autoantibodies and Clinical Phenotypes Correlate with the Aberrant Expression of Immune-Related MicroRNAs in Dermatomyositis
Table 1
Clinical features of the DM patients.
All
DM with ILD
DM without ILD
a value
Number of patients (n)
49
25
24
Age at onset (, years)
15
0.582
Sex (F/M)
33/16
19/6
14/10
Disease duration, mean of IQR months
19.04 (3.5–24)
21.56 (2.5–45)
17.22 (4.0–22.0)
0.561
Number of initial treatment, (%)
17 (34.6%)
9
8
Serological features
CRP (mg/dL)
0.133
ESR (mm/h)
0.006
CK (μ/L)
0.562
LDH (μ/L)
0.741
Ferritin (ng/mL)
0.336
Anti-Jo-1 antibody, (%)
5 (10.2%)
5
0
Anti-MDA5 antibody, (%)
11 (22.4%)
10
1
Anti-TIF1-γ antibody, (%)
8 (16.3%)
0
8
Anti-NXP2 antibody, (%)
6 (12.2%)
1
5
Anti-PL-7 antibody, (%)
4 (8.2%)
4
0
Anti-PL-12 antibody, (%)
0
0
0
Anti-OJ antibody, (%)
0
0
0
Anti-EJ antibody, (%)
2 (4.8%)
2
0
Anti-SAE antibody, (%)
2 (4.8%)
1
1
Anti-Mi2 antibody, (%)
2 (4.8%)
0
2
Anti-SRP antibody, (%)
1 (2.4%)
1
0
HMGCR antibody, (%)
1 (2.4%)
0
1
MSA negative, (%)
9 (18.4%)
2
7
Pulmonary function test, (%)
26 (53%)
19
7
FEV1
0.022
FVC
0.071
DLCO
0.014
PGA-VAS
0.321
Average values or numbers of each group are shown. Standard deviation (SD), interquartile range (IQR), or percentages are shown. DM: dermatomyositis; ILD: interstitial lung disease; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; CK: creatine kinase; LDH: lactate dehydrogenase; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; DLCO: carbon monoxide diffusing capacity; PGA: physician’s global assessment; VAS: visual analogue scale. The results of ferritin were partially missed. Data were available for 29 patients. a value: between DM with ILD and DM without ILD patients.
